

1/18

Analysis of Her-Tox binding to Her2 receptor




FIG. 1




FIG. 2





FIG. 3


4/18

Proliferation Assay with HCC 1954 Breast Cancer Line and Dolastatin Linker Derivative

**FIG. 4**


5/18

Proliferation Assay with HCC 1954 Breast Cancer Line and Her-tox conjugates

**FIG. 5**


6/18

Proliferation Assay with SKOV-3 Ovarian Cancer Line and Dolastatin Linker Derivatives

**FIG. 6**


7/18

Proliferation Assay with SKOV-3 Ovarian Cancer Line and Her-tox conjugates

**FIG. 7**

8/18

**Proliferation Assay with MDA-MB-468 Breast Cancer
Line and Dolastatin Linker Derivatives**

**FIG. 8**

9/18

Proliferation Assay with MDA-MB-468 Breast Cancer Line and Her-tox Conjugates




FIG. 9

10/18




FIG. 10

11/18

Assay Formats Used to Measure HER2-linked Dolastatin Derivative Concentration in SD Rat Serum

Small Molecule(SM)- Dolastatin





FIG. 11

12/18

**Rat PK Results: Serum concentrations of Transtuzumab-Linked
Dolastatin Derivatives**

Rat PK data with Trastuzumab-Linked Dolastatin Derivatives




FIG. 13

In vivo stability measurements detecting at least two dolastatin derivatives linked to transtuzumab




FIG. 14

Rat PK data with Trastuzumab -Linked Dolastatin Derivatives

HCC1954-e202 Group Mean Summary Data (TV = 1000 mm³ or Day 60)




FIG. 15

16/18






FIG. 16

17/18

Anti-tumor Efficacy of Dolastatin Linker Derivatives**FIG. 17**

18/18

Anti-tumor Efficacy of Dolastatin Linker Derivatives**FIG. 18**